Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CLBS Caladrius Biosciences (CLBS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Caladrius Biosciences Stock (NASDAQ:CLBS) 30 days 90 days 365 days Advanced Chart Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Donald Trump and his team just announced a brand new crypto project... They believe right now could be the perfect buying opportunity… And you have the chance to be a part of it! Claim your free ticket to the event now… Get Caladrius Biosciences alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.43▼$8.3852-Week Range N/AVolume466,373 shsAverage Volume522,308 shsMarket Capitalization$26.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCaladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Read More… Crypto Crash Ahead? (27 Experts Weigh In) (Ad)Donald Trump and his team just announced a brand new crypto project... They believe right now could be the perfect buying opportunity… And you have the chance to be a part of it! Claim your free ticket to the event now… Receive CLBS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caladrius Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address CLBS Stock News HeadlinesHARBOUR BIOMED LAUNCHES NONA BIOSCIENCES' "IDEAS TO IND" PRECLINICAL SOLUTIONS BUSINESS TO ACCELERATE GLOBAL BIOTHERAPEUTIC INNOVATIONDecember 1, 2022 | finance.yahoo.comCaladrius Biosciences, Inc.: Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 16, 2022 | finanznachrichten.deTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…October 5, 2024 | Porter & Company (Ad)Caladrius Biosciences, Inc.: Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 15, 2022 | finanznachrichten.deCaladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata TherapeuticsSeptember 15, 2022 | finance.yahoo.comCLBS Caladrius Biosciences, Inc.September 14, 2022 | seekingalpha.comCaladrius Biosciences Announces Approval of Merger and Name Change to Lisata TherapeuticsSeptember 14, 2022 | finance.yahoo.comHow to get the Protea Caladrius collection in Warframe: VeilbreakerSeptember 8, 2022 | msn.comSee More Headlines CLBS Stock Analysis - Frequently Asked Questions How were Caladrius Biosciences' earnings last quarter? Caladrius Biosciences, Inc. (NASDAQ:CLBS) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($1.80) earnings per share for the quarter, beating the consensus estimate of ($1.95) by $0.15. When did Caladrius Biosciences' stock split? Shares of Caladrius Biosciences reverse split on Thursday, September 15th 2022. The 1-15 reverse split was announced on Thursday, September 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Caladrius Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Caladrius Biosciences investors own include Brainstorm Cell Therapeutics (BCLI), HubSpot (HUBS), Karyopharm Therapeutics (KPTI), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX) and Energy Transfer (ET). Company Calendar Last Earnings11/04/2021Today10/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolNASDAQ:CLBS CUSIPN/A CIK320017 Webwww.caladrius.com Phone(908) 842-0100Fax646-514-7787Employees27Year Founded2006Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-27.24% Return on Assets-26.08% Debt Debt-to-Equity RatioN/A Current Ratio22.33 Quick Ratio22.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / BookN/AMiscellaneous Outstanding Shares60,583,000Free Float59,250,000Market Cap$26.05 million OptionableOptionable Beta0.91 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:CLBS) was last updated on 10/5/2024 by MarketBeat.com Staff From Our PartnersKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredGolden Equation: Volatility = OpportunityWhen the market swings wildly, most investors panic… But it doesn't have to be this way. You see, when t...Prosper Trading Academy | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caladrius Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caladrius Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.